TY - JOUR
T1 - HOX cluster-embedded lncRNAs and epithelial-mesenchymal transition in cancer
T2 - Molecular mechanisms and therapeutic opportunities
AU - Shenoy, U. Sangeetha
AU - Adiga, Divya
AU - Gadicherla, Srikanth
AU - Kabekkodu, Shama Prasada
AU - Hunter, Keith D.
AU - Radhakrishnan, Raghu
N1 - Funding Information:
Wellcome Trust DBT India Alliance , Government of India (Grant No. IA/CPHI/18/1/503927 ), Joint CSIR-UGC NET JuniorSenior Research Fellowship , Government of India (File No. 09/1165(0011)/2020-EMR-I ) and ICMR SRF , Government of India ( 2019/4115/CMB/BMS ).
Funding Information:
This work was supported by the DBT/Wellcome Trust India Alliance Fellowship, (Grant number - IA/CPHI/18/1/503927) awarded to Raghu Radhakrishnan.
Publisher Copyright:
© 2022
PY - 2023/1
Y1 - 2023/1
N2 - Although there has been substantial improvement in the treatment modalities, cancer remains the major cause of fatality worldwide. Metastasis, recurrence, and resistance to oncological therapies are the leading causes of cancer mortality. Epithelial-mesenchymal transition (EMT) is a complex biological process that allows cancer cells to undergo morphological transformation into a mesenchymal phenotype to acquire invasive potential. It encompasses reversible and dynamic ontogenesis by neoplastic cells during metastatic dissemination. Hence, understanding the molecular landscape of EMT is imperative to identify a reliable clinical biomarker to combat metastatic spread. Accumulating evidence reveals the role of HOX (homeobox) cluster-embedded long non-coding RNAs (lncRNAs) in EMT and cancer metastasis. They play a crucial role in the induction of EMT, modulating diverse biological targets. The present review emphasizes the involvement of HOX cluster-embedded lncRNAs in EMT as a molecular sponge, chromatin remodeler, signaling regulator, and immune system modulator. Furthermore, the molecular mechanisms behind therapy resistance and the potential use of novel drugs targeting HOX cluster-embedded lncRNAs in the clinical management of distant metastasis will be discussed.
AB - Although there has been substantial improvement in the treatment modalities, cancer remains the major cause of fatality worldwide. Metastasis, recurrence, and resistance to oncological therapies are the leading causes of cancer mortality. Epithelial-mesenchymal transition (EMT) is a complex biological process that allows cancer cells to undergo morphological transformation into a mesenchymal phenotype to acquire invasive potential. It encompasses reversible and dynamic ontogenesis by neoplastic cells during metastatic dissemination. Hence, understanding the molecular landscape of EMT is imperative to identify a reliable clinical biomarker to combat metastatic spread. Accumulating evidence reveals the role of HOX (homeobox) cluster-embedded long non-coding RNAs (lncRNAs) in EMT and cancer metastasis. They play a crucial role in the induction of EMT, modulating diverse biological targets. The present review emphasizes the involvement of HOX cluster-embedded lncRNAs in EMT as a molecular sponge, chromatin remodeler, signaling regulator, and immune system modulator. Furthermore, the molecular mechanisms behind therapy resistance and the potential use of novel drugs targeting HOX cluster-embedded lncRNAs in the clinical management of distant metastasis will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=85142906936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142906936&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2022.188840
DO - 10.1016/j.bbcan.2022.188840
M3 - Review article
C2 - 36403923
AN - SCOPUS:85142906936
SN - 0304-419X
VL - 1878
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 1
M1 - 188840
ER -
